Julie B Feder sold $302k of AURA
Chief Financial Officer at Aura Biosciences, Inc.. 25,131 shares at an average of $12.03, traded Oct 18, 2024, filed Oct 21, 2024.
Score components
- +22RoleCFO
- +14Trade size$302k at market
- +5Share of holdings soldSold 16% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -24.9%, 3m -33.3%, 6m -52.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-116029, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 18, 2024 | MOption exercise Common Stock10b5-1 | +17,500 | $2.74 | $48k | 151,776 | Oct 21, 2024 |
| Oct 18, 2024 | MOption exercise Common Stock10b5-1 | +2,631 | $4.25 | $11k | 154,407 | Oct 21, 2024 |
| Oct 18, 2024 | MOption exercise Common Stock10b5-1 | +5,000 | $5.48 | $27k | 159,407 | Oct 21, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stock10b5-1 | -25,131 | $12.03 | $302k | 134,276 | Oct 21, 2024 |
| Oct 18, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,500 | $0.00 | $0 | 68,257 | Oct 21, 2024 |
| Oct 18, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,631 | $0.00 | $0 | 32,359 | Oct 21, 2024 |
| Oct 18, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 120,547 | Oct 21, 2024 |
Related signals
Other insiders at Aura Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | AURAsell Aura Biosciences, Inc. | Anthony S Gibney See Remarks | $82k 12,824 shares | -5% | |
| 57Moderate | AURAsell Aura Biosciences, Inc. | Matrix Capital Management Company, LP owner | $39M 6,922,870 shares | -100% | |
| 24Weak | AURAsell Aura Biosciences, Inc. | Conor Kilroy See Remarks | $82k 11,738 shares | -5% | |
| 48Moderate | Aura Biosciences, Inc. | Pinos Elisabet de los See Remarks | $241k 47,648 shares | -10% | |
| 41Moderate | Aura Biosciences, Inc. | Amy Elazzouzi Senior Vice President, Finance | $43k 8,549 shares | -10% | |
| 40Moderate | Aura Biosciences, Inc. | Janet Jill Hopkins Chief Medical Officer | $103k 20,401 shares | -8% | |
| 39Weak | Aura Biosciences, Inc. | Mark Plavsic Chief Technology Officer | $80k 15,890 shares | -8% | |
| 37Weak | Aura Biosciences, Inc. | Conor Kilroy See Remarks | $61k 12,079 shares | -7% | |
| 32Weak | Aura Biosciences, Inc. | Pinos Elisabet de los See Remarks | $82k 16,928 shares | -4% | |
| 23Weak | Aura Biosciences, Inc. | Amy Elazzouzi Senior Vice President, Finance | $7,684 1,581 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.